UnitedHealth's medical benefit ratio fell 270 basis points to 86.7% in the second quarter of 2026, while Elevance Health's benefit expense ratio rose 80 basis points to 89.7% over the same three months (UnitedHealth Group, July 16, 2026; Elevance Health, July 15, 2026). Both insurers raised full-year guidance anyway, which means the split is not a trend story. It is a pricing and reserving story, and it lives in the assumptions each set roughly a year ago.

Trade coverage of the two prints has mostly settled on a single frame: managed care is recovering from the 2024-2025 cost shock, and UNH's beat is exhibit one. That framing survives only until Elevance's number sits next to it. Two of the industry's largest actuarial pricing operations, covering close to 100 million combined medical members, moved their loss ratios in opposite directions in the same 13-week window. A single-direction "recovery" narrative cannot explain that. A book-specific one can.

The 270-Point Swing: Decomposing UnitedHealth's Beat

UnitedHealth's second-quarter medical care ratio of 86.7% compared with 89.4% in the second quarter of 2025, a 270 basis point improvement that beat the sell-side consensus estimate of roughly 88.5% by close to 180 basis points (UnitedHealth Group Q2 2026 earnings release, July 16, 2026). The company followed with a guidance raise: full-year 2026 adjusted earnings per share moved to a range of $19.50 to $20.00, up from the prior floor of at least $18.25, while revenue guidance held at greater than $439 billion (UnitedHealth Group, July 16, 2026). Adjusted EPS for the quarter itself came in at $6.38 against a consensus estimate near $4.90, and diluted EPS of $6.04 compared with $3.74 a year earlier.

New CEO Stephen Hemsley, who replaced Andrew Witty after the company suspended guidance during the 2025 cost shock, framed the quarter as evidence of "continuing progress toward delivering more consistent and dependable performance" (Stephen Hemsley, UnitedHealth Group Q2 2026 earnings call, July 16, 2026). The company's own commentary pointed to three levers behind the ratio improvement: Medicare Advantage benefit redesign, tighter provider network management, and pricing that was set closer to realized cost than the assumptions that produced 2024's blowout. Management told analysts that 2026 Medicare medical cost trend should finish below its initial estimate of roughly 10%, helped by a milder respiratory illness season, while commercial trend is running modestly above 11%, a level the company flagged as an ongoing margin pressure point rather than a solved problem (UnitedHealth Group Q2 2026 earnings call, July 16, 2026).

Completion Factors, Not a Reserve Release: Reading the $860 Million Line

The single disclosure that separates a durable pricing story from a one-quarter reserve accounting story sits inside the ratio, not beside it. UnitedHealth's release states the medical care ratio "was affected by $860 million of net favorable prior period development, with the majority related to 2026 dates of service" (UnitedHealth Group Q2 2026 earnings release, July 16, 2026). That single sentence carries more actuarial weight than the headline ratio itself, and it cuts against the reading that would worry a valuation actuary most.

A dollar of favorable development tied to a prior calendar year is a release of margin that was built into reserves booked twelve or twenty-four months ago; it flatters the current quarter by borrowing against conservatism carried from an earlier period, and it does not recur once the redundant cushion is exhausted. A dollar of favorable development tied to the current year's dates of service is a different animal: it means claims incurred in 2026 are completing lower than the completion factors and trend assumptions used to set interim IBNR estimates earlier in the same year. That is a signal about current pricing and utilization, not a release of banked margin. UnitedHealth's own language, that the majority of the $860 million ties to 2026 dates of service, points toward the second, more durable reading.

The comparison to a year earlier sharpens the point. In the second quarter of 2025, UnitedHealth reported medical reserve development of $70 million unfavorable, "with nearly all related to 2025 dates of service" (UnitedHealth Group Q2 2025 earnings release, July 2025), the same current-year-completion dynamic running in the opposite direction during the year the company's Medicare Advantage and Optum Health cost estimates proved too optimistic. The swing between the two quarters, from a $70 million current-year miss to an $860 million current-year favorability, is roughly $930 million. Against UnitedHealthcare's $86.0 billion of Q2 2026 premium revenue (UnitedHealth Group, July 16, 2026), that swing alone works out to a little over 100 basis points, meaning close to 40% of the quarter's 270-point ratio improvement traces to completion factors landing better than assumed rather than to the pricing action alone. The remaining roughly 160 basis points is the more structural component: the 2026 Medicare Advantage rate action clearing realized trend, and the benefit redesign and network changes management cited on the call.

Elevance's 80-Point Miss: A Government Business Problem, Not a Portfolio One

Elevance Health's Q2 2026 benefit expense ratio of 89.7% rose 80 basis points from a year earlier, "driven by elevated medical cost trend in Government businesses, partially offset by improved performance in Individual ACA" (Elevance Health Q2 2026 earnings release, July 15, 2026). The company's Health Benefits segment carried $42.7 billion of operating revenue, up 3% year over year, on roughly 44.9 million medical members, down about 469,000 sequentially (Elevance Health Q2 2026 earnings call, July 15, 2026). Unlike UnitedHealth's mostly favorable print, Elevance's cost pressure was specific and named. Executives described Medicaid cost drivers as "concentrated in previously identified areas, including behavioral health, specialty pharmacy, outpatient surgery and emergency department utilization," and were explicit that membership and acuity remain "broadly aligned with assumptions," ruling out a fresh "stepwise acuity reset" as the culprit; the pressure instead comes from utilization intensity among members who remain enrolled (Elevance Health Q2 2026 earnings call, July 15, 2026). CFO Mark Kaye characterized 2026 as "the expected low point before profitability improves," with second-half Medicaid margin expected to benefit from July 1 rate updates already reflected in several states (Mark Kaye, Elevance Health Q2 2026 earnings call, July 15, 2026).

Medicare Advantage and Individual ACA moved the other way inside the same print, both performing ahead of plan, which is why the 80-point deterioration reads as narrower than the headline ratio suggests. Days claims payable stood at 45.4 as of June 30, 2026, down 1.2 days from March 31 but up 2.9 days from a year earlier (Elevance Health Q2 2026 Form 10-Q). A rising year-over-year claims-payable balance alongside a stated absence of prior-year reserve deficiencies is consistent with a company holding reserves more conservatively against elevated Medicaid utilization, rather than one that has been caught short by it, but the distinction will not be fully testable until the 2026 accident year matures further.

Two EPS Raises, Two Different Mechanisms

The detail that undercuts a simple "who priced better" reading is that Elevance raised guidance too, to at least $27.00 adjusted diluted EPS and at least $6.0 billion of operating cash flow, alongside a stated ambition to return to at least 12% adjusted EPS growth in 2027 (Elevance Health Q2 2026 earnings release, July 15, 2026). Quarterly adjusted diluted EPS of $7.45 beat a consensus estimate near $6.21, a beat of roughly 20%, aided in part by an approximately $0.80 per share net below-the-line benefit that sat outside the underwriting result entirely (Elevance Health Q2 2026 earnings call, July 15, 2026).

That is a structurally different kind of beat than UnitedHealth's. UNH's guidance raise is a direct read-through from a better medical benefit ratio: lower claims relative to premium flow straight to underwriting margin and from there to EPS. Elevance's raise leans more heavily on segment mix, Carelon's 6% operating revenue growth and $0.9 billion operating gain, and non-underwriting items, while the core Government benefit ratio moved against the company. Two insurers reporting the same headline metric, "guidance raised," in the same week can be running on entirely different actuarial engines underneath it. Reading the raise alone, without decomposing where it came from, would treat the two prints as more comparable than they are.

MetricUnitedHealth Q2 2026Elevance Q2 2026
Medical loss / benefit expense ratio86.7% (vs. 89.4% Q2 2025)89.7% (vs. 88.9% Q2 2025)
Direction vs. prior year−270 bps+80 bps
Adjusted EPS, quarter$6.38$7.45
Full-year adjusted EPS guidance$19.50–$20.00 (from >$18.25)At least $27.00
Primary driver named by managementMA pricing/benefit redesign plus favorable current-year completionElevated Medicaid utilization, offset by MA and ACA outperformance
Membership trendMA down 965K, Medicaid down 380K, commercial down 145K since YE2025Medical membership down ~469K sequentially

Membership Mix Is Doing More Work Than Either Earnings Call Admitted

Both insurers are shrinking, and both are shrinking on purpose, but the composition of what each is shedding explains a meaningful share of the ratio divergence on its own. UnitedHealth's Medicare Advantage membership fell 965,000 since year-end 2025 and Medicaid membership fell 380,000, driven in part by a planned Louisiana exit, while commercial membership contracted by 145,000, leaving total UnitedHealthcare medical membership down 525,000 sequentially (UnitedHealth Group Q2 2026 earnings release, July 16, 2026). A carrier that walks away from underpriced Medicaid and marginal Medicare Advantage counties mechanically improves its blended ratio, independent of any improvement in how it prices the business it keeps. Elevance is running the same playbook with a lag. CEO Gail Boudreaux confirmed the company will exit additional Medicaid markets over the next 12 to 18 months where management sees "no path to sustainable performance," describing the moves as "targeted portfolio actions" rather than a broad Medicaid retreat (Gail Boudreaux, Elevance Health Q2 2026 earnings call, July 15, 2026). The difference is timing, not strategy: UnitedHealth's Louisiana exit and membership shedding already ran through the Q2 2026 numbers, while Elevance's comparable exits are still ahead of it, in a book where the company chose in this cycle to hold share and absorb utilization rather than cut and run first. That sequencing gap, not a difference in underwriting philosophy, explains a real share of why one ratio improved and the other did not this quarter.

Read-Through to 2027 Bids and Rate Filings

Neither company's Q2 print settles what 2027 pricing should assume, and the two diverge on exactly the dimension 2027 bid actuaries need to resolve first. UnitedHealth's data argues that 2026 Medicare Advantage rate actions were sized correctly against realized trend, which supports holding a similar rate-to-trend spread into 2027 bids rather than widening it further. Elevance's data argues the opposite for Medicaid specifically: rate updates through mid-2026, even the favorable July 1 activity CFO Kaye cited, have not yet caught up to utilization concentrated in behavioral health, specialty pharmacy, and emergency department use, which is the same category of state-by-state rate adequacy gap that has pressured Medicaid-heavy carriers across the sector this cycle. The practical implication for actuaries pricing 2027 state Medicaid contracts is that a single blended "Medicaid is recovering" assumption, borrowed from the better-performing lines in the same earnings season, would understate the rate increases several states still need to approve. For Medicare Advantage bid actuaries, UnitedHealth's print is the more useful data point of the two, precisely because it isolates a pricing-and-trend story from a reserve-release story: the current-year completion favorability embedded in the $860 million disclosure is closer to real-time evidence that 2026 MA pricing cleared trend than a headline ratio alone would show. Carriers and consultants building 2027 competitor models off either print without decomposing reserve mechanics and membership mix first risk crediting pricing skill where the driver was really a planned exit, or crediting trend moderation where the driver was really an accounting classification of current-year IBNR.

Further Reading

Sources